Kuo Chih-Ling, Assefa Haregewein, Kamath Shantaram, Brzozowski Zdzialaw, Slawinski Jaroslaw, Saczewski Franciszek, Buolamwini John K, Neamati Nouri
Department of Pharmaceutical Sciences, School of Pharmacy, University of Southern California, 1985 Zonal Avenue, PSC 304, Los Angeles, California 90089, USA.
J Med Chem. 2004 Jan 15;47(2):385-99. doi: 10.1021/jm030378i.
An essential step in the HIV life cycle is integration of the viral DNA into the host chromosome. This step is catalyzed by a 32-kDa viral enzyme HIV integrase (IN). HIV-1 IN is an important and validated target, and the drugs that selectively inhibit this enzyme, when used in combination with reverse transcriptase (RT) and protease (PR) inhibitors, are believed to be highly effective in suppressing the viral replication. IN catalyzes two discrete enzymatic processes referred to as 3' processing and DNA strand transfer. As a part of a study to optimize new lead molecules we previously identified from a series of 2-mercaptobenzenesulfonamides (MBSAs), we applied three-dimensional quantitative structure-activity relationship methods, comparative molecular field analysis (CoMFA), and comparative molecular similarity indices analysis (CoMSIA) to training sets of up to 66 compounds. Two different conformational templates were used: Conf-d, obtained from docking into the HIV-1 IN active site and Conf-s obtained by a systematic conformational search, using lead compounds 1 and 14, respectively. Reliable models of good predictive power were obtained after removal of compounds with high residuals. The Conf-s models tended to perform better than the Conf-d models. Cross-validated coefficients (q(2)) of up to 0.719 (strand transfer CoMSIA, Conf-s) regression coefficients (r(2)) of up to 0.932 (strand transfer CoMSIA, Conf-d) were obtained, with the number of partial least squares (PLS) components varying from 3 to 6, and the number of outliers being 4 in most of the models. Because all biological data were determined under exactly the same conditions using the same enzyme preparation, our predictive models are promising for drug optimization. Therefore, these results combined with docking studies were used to guide the rational design of new inhibitors. Further synthesis of 12 new analogues was undertaken, and these were used as a test set for validation of the quantitative structure-activity relationship (QSAR) models. For compounds with closely related structures, binding energies given by the FlexX scoring function correlated with HIV-1 IN inhibitory activity.
HIV生命周期中的一个关键步骤是将病毒DNA整合到宿主染色体中。这一步骤由一种32 kDa的病毒酶HIV整合酶(IN)催化。HIV-1 IN是一个重要且经过验证的靶点,与逆转录酶(RT)和蛋白酶(PR)抑制剂联合使用时,选择性抑制该酶的药物被认为在抑制病毒复制方面非常有效。IN催化两个不同的酶促过程,即3'加工和DNA链转移。作为我们先前从一系列2-巯基苯磺酰胺(MBSA)中鉴定出的新先导分子优化研究的一部分,我们将三维定量构效关系方法、比较分子场分析(CoMFA)和比较分子相似性指数分析(CoMSIA)应用于多达66种化合物的训练集。使用了两种不同的构象模板:Conf-d,通过对接HIV-1 IN活性位点获得;Conf-s,通过系统构象搜索获得,分别使用先导化合物1和14。去除具有高残差的化合物后,获得了具有良好预测能力的可靠模型。Conf-s模型的表现往往优于Conf-d模型。交叉验证系数(q(2))高达0.719(链转移CoMSIA,Conf-s),回归系数(r(2))高达0.932(链转移CoMSIA,Conf-d),偏最小二乘(PLS)成分数量从3到6不等,大多数模型中的异常值数量为4。由于所有生物学数据都是在完全相同的条件下使用相同的酶制剂测定的,我们的预测模型在药物优化方面很有前景。因此,这些结果与对接研究相结合,用于指导新抑制剂的合理设计。进一步合成了12种新类似物,并将其用作验证定量构效关系(QSAR)模型的测试集。对于结构密切相关的化合物,FlexX评分函数给出的结合能与HIV-1 IN抑制活性相关。